Shanghai Serum Bio-Technology Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shanghai Sailun Biotechnology Co., Ltd. was established in 1999 and is a biopharmaceutical high-tech enterprise specializing in anti toxin and anti serum. On March 11, 2022, the company was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688163). The company's main products include horse tetanus immunoglobulin (F (ab ') 2), anti snake venom serum series products, and anti rabies serum, all of which have been included in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue (2017 Edition)" issued by the Ministry of Human Resources and Social Security. The horse tetanus immunoglobulin (F (ab') 2) and anti snake venom serum series were included in the "Emergency (Emergency) and Rescue Drug Direct Online Procurement Demonstration Drug Catalogue" issued by the National Health and Family Planning Commission in 2015. Among them, horse tetanus immunoglobulin (F (ab ') 2) is a "new generation tetanus antitoxin product" developed by the company using modern column chromatography purification technology and improving traditional tetanus antitoxin production process. Its application has significantly reduced the positive reaction rate caused by heterologous proteins, and significantly reduced the incidence of allergic reactions and serum diseases; The anti snake venom serum series products are special first-aid drugs for snake wound treatment, making contributions to saving lives. The company has a vision of "providing the best care for more lives" and a mission of "cherishing life with all our heart and protecting health with all our strength". Based on the field of anti toxin and anti serum, the company relies on core technology for independent research and development, forming a technological advantage in the research and production of anti toxin and anti serum products; Increase investment in independent research and development, develop new technologies, and improve product technology platforms to further enrich product pipelines; At the same time, we will continue to invest in the construction of the emergency service network, enhance the company's ability to provide emergency medicine treatment services, improve the market application level of our products, and ensure people's lives and health. |
| Headquarter | Shanghai |
| Establish Date | 11/9/1999 |
| Listed Code | 688163.SH |
| Listed Date | 3/11/2022 |
| Chairman | Fan Zhihe, Fan Tiejiong. |
| CEO | Fan Tiejiong. |
| Website | www.serum-china.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
